Drug Search Results
More Filters [+]

Diclofenamide

Alternative Names: diclofenamide, dichlorphenamide, keveyis, daranide
Latest Update: 2017-06-14
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: CA Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Austria | Germany | India | Ireland | Italy | Korea | New Zealand | Pakistan | Taiwan | United Kingdom | United States

Approved Indications: Paralysis | Hypokalemic Periodic Paralysis | Paralysis, Hyperkalemic Periodic

Known Adverse Events: Confusion | Dysgeusia | Paresthesia

Company: University of Rochester
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Diclofenamide

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Hypokalemic Periodic Paralysis|Myotonia Congenita|Paralysis, Hyperkalemic Periodic|Myotonic Disorders

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2008-002306-19

P3

Completed

Paralysis, Hyperkalemic Periodic|Hypokalemic Periodic Paralysis

2013-05-05

HYP-HOP

P3

Completed

Paralysis, Hyperkalemic Periodic|Hypokalemic Periodic Paralysis

2013-04-01

OSU-92H0173

P3

Completed

Hypokalemic Periodic Paralysis|Myotonia Congenita|Paralysis, Hyperkalemic Periodic|Myotonic Disorders

None

Recent News Events

Date

Type

Title